Hikma’s Vascepa Generic Approved But Launch Still A Mystery

Follows Favorable US District Court Ruling In March

26 May 2020

Hikma has eyes on launching a generic of Amarin’s Vascepa in the US following FDA approval and a favorable patent ruling at the district level in March. However, with a swift appeal filed by the originator in the works, the Jordanian firm is yet to pull the trigger.

Pills form question mark — The launch plans for Hikma's Vascepa generic are a closely guarded secret for now • Source: Shutterstock

Analysts remain skeptical that Hikma Pharmaceuticals will choose to launch ‘at-risk’ its generic Vascepa (icosapent ethyl) 1g capsules in the US, after the company announced receipt of US Food and Drug Administration approval.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

02 May 2025

• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

01 May 2025

• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

01 May 2025

• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Iconovo Slims Down As It Focuses On Commercialization

29 Apr 2025

• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

J&J Denied Injunction Over Private-Label Ustekinumab In US

01 May 2025

• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.